Company intelligence / Profile preview

Sequella, Inc.

Rockville, Maryland, United Statessequella.com ↗

Ownership: Private
Employees: ~3
Development stage: Phase 2

Overview

Sequella has developed SQ109, a drug candidate for tuberculosis treatment that has progressed to clinical trials. They filed a second IND for SQ109 for treatment of Helicobacter pylori infections in 2010. The company has licensed rights to commercialize SQ109 for tuberculosis in Russia and neighboring Commonwealth of Independent States countries.

Therapeutic areas: Infectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

5 assets

sutezolid

4 more assets in the full pipeline.

Request access →

Partnerships

National Institute of Allergy and Infectious Diseases (NIAID)National Institutes of Health (NIH)Maxwell Biotech Venture Fund

Beyond the preview

Go deeper on Sequella, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sequella, Inc..

Explore the full profile